Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate

M F Pinard, J Jolivet, M Ratnam, I Kathmann, C Molthoff, R Westerhof, J H Schornagel, G Jansen

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Two methotrexate (MTX)-resistant human breast-cancer cell lines with impaired transport via the reduced folate carrier (RFC), one established in vitro (MTX(R)-ZR-75-1) and another inherently resistant (MDA-231), were adapted to grow in medium containing 2 nM folic acid. This induced the expression of previously undetectable membrane folate receptors (MFR) to levels of 8.2 and 2.3 pmol/10(7) cells, respectively. Polymerase chain reaction (PCR) quantitation revealed that MFR messenger-RNA levels of the isoform first described in human nasopharyngeal carcinoma KB cells (MFR-alpha) were increased in low-folate-adapted MTX(R)-ZR-75-1 cells, whereas placental transcripts (MFR-beta) coincided with MFR-alpha expression in low-folate (LF)-adapted MDA-231 cells. These cell lines were used to study the role of MFR in the uptake and growth-inhibitory effects of five different antifolates with varying affinities for MFR: N10-propargyl-5, 8-dideazafolic acid (CB3717) > 5,10-dideazatetra-hydrofolic acid (DDATHF) > N-5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-methyl) -N-methyl-amino]-2-theonyl}-glutamic acid (ZD1694) > MTX > edatrexate (EDX). Expression of MFR only slightly decreased the resistant phenotype for MTX, EDX, and ZD1694, suggesting that these drugs are not transported intracellularly to cytotoxic concentrations at these levels of MFR expression. On the other hand, both cell lines became from at least 180- to 400-fold more sensitive to growth inhibition by CB3717 and DDATHF, which may be correlated with their high affinity for MFR. These sensitivity/resistance profiles were largely similar following cell culture in medium containing 1 nM L-leucovorin, a folate with an affinity for MFR 10-fold lower than that of folic acid, the one exception being the increased sensitivity for ZD1694 seen in the LF-adapted cells with the highest level of MFR expression (MTX(R)-ZR-75-1). These results illustrate that the efficacy of MFR in mediating antifolate transport and cytotoxicity depends on their affinity for the folate antagonist, their degree of expression, and the levels of competing folates.

Original languageEnglish
Pages (from-to)281-8
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume38
Issue number3
DOIs
Publication statusPublished - 1996

Cite this

Pinard, M F ; Jolivet, J ; Ratnam, M ; Kathmann, I ; Molthoff, C ; Westerhof, R ; Schornagel, J H ; Jansen, G. / Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate. In: Cancer Chemotherapy and Pharmacology. 1996 ; Vol. 38, No. 3. pp. 281-8.
@article{fb3b9806e65b4467b5537361e0e2b59d,
title = "Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate",
abstract = "Two methotrexate (MTX)-resistant human breast-cancer cell lines with impaired transport via the reduced folate carrier (RFC), one established in vitro (MTX(R)-ZR-75-1) and another inherently resistant (MDA-231), were adapted to grow in medium containing 2 nM folic acid. This induced the expression of previously undetectable membrane folate receptors (MFR) to levels of 8.2 and 2.3 pmol/10(7) cells, respectively. Polymerase chain reaction (PCR) quantitation revealed that MFR messenger-RNA levels of the isoform first described in human nasopharyngeal carcinoma KB cells (MFR-alpha) were increased in low-folate-adapted MTX(R)-ZR-75-1 cells, whereas placental transcripts (MFR-beta) coincided with MFR-alpha expression in low-folate (LF)-adapted MDA-231 cells. These cell lines were used to study the role of MFR in the uptake and growth-inhibitory effects of five different antifolates with varying affinities for MFR: N10-propargyl-5, 8-dideazafolic acid (CB3717) > 5,10-dideazatetra-hydrofolic acid (DDATHF) > N-5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-methyl) -N-methyl-amino]-2-theonyl}-glutamic acid (ZD1694) > MTX > edatrexate (EDX). Expression of MFR only slightly decreased the resistant phenotype for MTX, EDX, and ZD1694, suggesting that these drugs are not transported intracellularly to cytotoxic concentrations at these levels of MFR expression. On the other hand, both cell lines became from at least 180- to 400-fold more sensitive to growth inhibition by CB3717 and DDATHF, which may be correlated with their high affinity for MFR. These sensitivity/resistance profiles were largely similar following cell culture in medium containing 1 nM L-leucovorin, a folate with an affinity for MFR 10-fold lower than that of folic acid, the one exception being the increased sensitivity for ZD1694 seen in the LF-adapted cells with the highest level of MFR expression (MTX(R)-ZR-75-1). These results illustrate that the efficacy of MFR in mediating antifolate transport and cytotoxicity depends on their affinity for the folate antagonist, their degree of expression, and the levels of competing folates.",
keywords = "Aminopterin/analogs & derivatives, Antimetabolites, Antineoplastic/metabolism, Binding Sites, Breast Neoplasms/pathology, Carrier Proteins/drug effects, Cell Membrane/drug effects, DNA, Complementary/metabolism, Female, Folate Receptors, GPI-Anchored, Folic Acid/analogs & derivatives, Folic Acid Antagonists/metabolism, Humans, Methotrexate/metabolism, Polymerase Chain Reaction, Quinazolines/metabolism, RNA, Messenger/metabolism, Receptors, Cell Surface/drug effects, Spectrometry, Fluorescence, Structure-Activity Relationship, Tetrahydrofolates/metabolism, Thiophenes/metabolism, Tumor Cells, Cultured/drug effects",
author = "Pinard, {M F} and J Jolivet and M Ratnam and I Kathmann and C Molthoff and R Westerhof and Schornagel, {J H} and G Jansen",
year = "1996",
doi = "10.1007/s002800050483",
language = "English",
volume = "38",
pages = "281--8",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate. / Pinard, M F; Jolivet, J; Ratnam, M; Kathmann, I; Molthoff, C; Westerhof, R; Schornagel, J H; Jansen, G.

In: Cancer Chemotherapy and Pharmacology, Vol. 38, No. 3, 1996, p. 281-8.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate

AU - Pinard, M F

AU - Jolivet, J

AU - Ratnam, M

AU - Kathmann, I

AU - Molthoff, C

AU - Westerhof, R

AU - Schornagel, J H

AU - Jansen, G

PY - 1996

Y1 - 1996

N2 - Two methotrexate (MTX)-resistant human breast-cancer cell lines with impaired transport via the reduced folate carrier (RFC), one established in vitro (MTX(R)-ZR-75-1) and another inherently resistant (MDA-231), were adapted to grow in medium containing 2 nM folic acid. This induced the expression of previously undetectable membrane folate receptors (MFR) to levels of 8.2 and 2.3 pmol/10(7) cells, respectively. Polymerase chain reaction (PCR) quantitation revealed that MFR messenger-RNA levels of the isoform first described in human nasopharyngeal carcinoma KB cells (MFR-alpha) were increased in low-folate-adapted MTX(R)-ZR-75-1 cells, whereas placental transcripts (MFR-beta) coincided with MFR-alpha expression in low-folate (LF)-adapted MDA-231 cells. These cell lines were used to study the role of MFR in the uptake and growth-inhibitory effects of five different antifolates with varying affinities for MFR: N10-propargyl-5, 8-dideazafolic acid (CB3717) > 5,10-dideazatetra-hydrofolic acid (DDATHF) > N-5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-methyl) -N-methyl-amino]-2-theonyl}-glutamic acid (ZD1694) > MTX > edatrexate (EDX). Expression of MFR only slightly decreased the resistant phenotype for MTX, EDX, and ZD1694, suggesting that these drugs are not transported intracellularly to cytotoxic concentrations at these levels of MFR expression. On the other hand, both cell lines became from at least 180- to 400-fold more sensitive to growth inhibition by CB3717 and DDATHF, which may be correlated with their high affinity for MFR. These sensitivity/resistance profiles were largely similar following cell culture in medium containing 1 nM L-leucovorin, a folate with an affinity for MFR 10-fold lower than that of folic acid, the one exception being the increased sensitivity for ZD1694 seen in the LF-adapted cells with the highest level of MFR expression (MTX(R)-ZR-75-1). These results illustrate that the efficacy of MFR in mediating antifolate transport and cytotoxicity depends on their affinity for the folate antagonist, their degree of expression, and the levels of competing folates.

AB - Two methotrexate (MTX)-resistant human breast-cancer cell lines with impaired transport via the reduced folate carrier (RFC), one established in vitro (MTX(R)-ZR-75-1) and another inherently resistant (MDA-231), were adapted to grow in medium containing 2 nM folic acid. This induced the expression of previously undetectable membrane folate receptors (MFR) to levels of 8.2 and 2.3 pmol/10(7) cells, respectively. Polymerase chain reaction (PCR) quantitation revealed that MFR messenger-RNA levels of the isoform first described in human nasopharyngeal carcinoma KB cells (MFR-alpha) were increased in low-folate-adapted MTX(R)-ZR-75-1 cells, whereas placental transcripts (MFR-beta) coincided with MFR-alpha expression in low-folate (LF)-adapted MDA-231 cells. These cell lines were used to study the role of MFR in the uptake and growth-inhibitory effects of five different antifolates with varying affinities for MFR: N10-propargyl-5, 8-dideazafolic acid (CB3717) > 5,10-dideazatetra-hydrofolic acid (DDATHF) > N-5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-methyl) -N-methyl-amino]-2-theonyl}-glutamic acid (ZD1694) > MTX > edatrexate (EDX). Expression of MFR only slightly decreased the resistant phenotype for MTX, EDX, and ZD1694, suggesting that these drugs are not transported intracellularly to cytotoxic concentrations at these levels of MFR expression. On the other hand, both cell lines became from at least 180- to 400-fold more sensitive to growth inhibition by CB3717 and DDATHF, which may be correlated with their high affinity for MFR. These sensitivity/resistance profiles were largely similar following cell culture in medium containing 1 nM L-leucovorin, a folate with an affinity for MFR 10-fold lower than that of folic acid, the one exception being the increased sensitivity for ZD1694 seen in the LF-adapted cells with the highest level of MFR expression (MTX(R)-ZR-75-1). These results illustrate that the efficacy of MFR in mediating antifolate transport and cytotoxicity depends on their affinity for the folate antagonist, their degree of expression, and the levels of competing folates.

KW - Aminopterin/analogs & derivatives

KW - Antimetabolites, Antineoplastic/metabolism

KW - Binding Sites

KW - Breast Neoplasms/pathology

KW - Carrier Proteins/drug effects

KW - Cell Membrane/drug effects

KW - DNA, Complementary/metabolism

KW - Female

KW - Folate Receptors, GPI-Anchored

KW - Folic Acid/analogs & derivatives

KW - Folic Acid Antagonists/metabolism

KW - Humans

KW - Methotrexate/metabolism

KW - Polymerase Chain Reaction

KW - Quinazolines/metabolism

KW - RNA, Messenger/metabolism

KW - Receptors, Cell Surface/drug effects

KW - Spectrometry, Fluorescence

KW - Structure-Activity Relationship

KW - Tetrahydrofolates/metabolism

KW - Thiophenes/metabolism

KW - Tumor Cells, Cultured/drug effects

U2 - 10.1007/s002800050483

DO - 10.1007/s002800050483

M3 - Article

VL - 38

SP - 281

EP - 288

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -